eisai-europe-limited

Médias

Eisai Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven® (Eribulin) Across the Middle East

Médias

Eisai Expands Marketing and Supply Agreement for Anti-obesity Agent Lorcaserin to Include Most Countries Worldwide

Médias

Eisai's EMEA Operation Becomes the US Supply Centre for Epilepsy Drug Zonegran® (zonisamide)

Médias

New First-in-class Epilepsy Treatment Fycompa® (perampanel) Approved In Israel

Médias

Italian Medicines Agency (AIFA) Approves the Reimbursement of Zonegran® (zonisamide) Monotherapy Treatment for Adults with Newly Diagnosed Partial Epilepsy

Médias

Eisai Begins Free Supply of Diethylcarbamazine in Line With its Global Commitment to Eliminate Lymphatic Filariasis

Médias

Se presenta en España la nueva formulación en suspensión oral de Inovelon®(rufinamida)

Médias

Inovelon® (rufinamide) Oral Suspension Formulation Launched in Spain

Médias

El Consorcio Escocés de Medicamentos aprueba Fycompa® (perampanel)

Médias

Se anuncian los resultados del estudio comparativo de fase III de Halaven® (eribulina) frente a capecitabina (Xeloda®) en pacientes con cáncer de mama metastásico o localmente avanzado

Médias

El grupo Galés AWMSG y el Consorcio Escocés de Medicamentos aceptan el uso de la nueva presentación bebible y apta para niños de Inovelon® (rufinamida)

Médias

Nuevos estudios sobre Zebinix® presentados en el principal Congreso Europeo de Epilepsia

Médias

La presentación de los primeros datos de un metanálisis de estudios en fase III avala el tratamiento contra la epilepsia parcial más reciente de Europa

Médias

Le Scottish medicines consortium donne un avis favorable à l'utilisation de Fycompa® (pérampanel), traitement anti-épileptique en prise unique quotidienne

Médias

Resultats annonces pour l'etude de phase III comparant Halaven® (eribuline) a la capecitabine (Xeloda®) chez des patientes atteintes de cancer du sein localement avance ou metastatique

Médias

Le All Wales Strategic Medical Group (AWSMG) et le Scottish Medicines Consortium donnent leur autorisation au remboursement d'Inovelon® (rufinamide) en solution buvable, présentation adaptée à l'usage en pédiatrie

Médias

Presentation de nouvelles etudes relatives a ZEBINIX® (eslicarbazépine) lors d'un important Congres Europeen sur l'épilepsie

Médias

Les resultats de nouvelles etudes relatives a l'antiepileptique ZONEGRAN® d'Eisai (zonisamide), ont ete presentes lors du Congrès Europeen sur l'epilepsie (ECE)

Médias

Eisai Disagrees with German Institute for Quality and Efficiency in Health Care (IQWiG) Report on Innovative Antiepileptic Drug Fycompa® (Perampanel) for the Treatment of Partial Epilepsy

Médias

Eisai and UCL Form Major Drug Discovery Alliance to Develop New Therapeutics for Neurological Diseases

Médias

Scottish Medicines Consortium Approves Fycompa® (Perampanel) - Once Daily Anti-Epileptic Treatment

Médias

Results Announced for Phase III Head-to-head Study of Halaven® (eribulin) Versus Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

Médias

Eisai to Present New Research on Halaven (Eribulin) at 35th Annual San Antonio Breast Cancer Symposium

Médias

All Wales Strategic Medical Group Approves Zebinix® (Eslicarbazepine Acetate) - Once Daily Anti-Epileptic Treatment

Médias

All Wales Strategic Medical Group and Scottish Medicines Consortium Accept use of Inovelon® (rufinamide) Drinkable, Child-friendly Formulation

Médias

Eisai's Halaven First Breast Cancer Therapy for Which Price Negotiations with the National Association of Statutory Health Insurance Funds were Successfully Concluded

Médias

First Presentation of Pooled Phase III Data Supporting Europe's Newest Partial Epilepsy Treatment

Médias

New Research on Eisai's Antiepileptic Drug Zonegran®(Zonisamide) Presented at European Congress on Epileptology (ECE)

Médias

New Studies on Zebinix® Presented at Leading European Epilepsy Congress

Médias

Eisai Presents new Research for Investigational Compound Lenvatinib at the European Society for Medical Oncology